EMBECTA CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.37 USD | -0.48% |
|
-5.79% | -34.65% |
| May. 16 | Transcript : Embecta Corp. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM | |
| May. 09 | Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup | DJ |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Its low valuation, with P/E ratio at 10.18 and 7.47 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- This company will be of major interest to investors in search of a high dividend stock.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Most analysts recommend that the stock should be sold or reduced.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -34.65% | 713M | - | ||
| -7.16% | 178B | C+ | ||
| -1.23% | 107B | C | ||
| -4.86% | 67.04B | A | ||
| -4.28% | 47.23B | B- | ||
| +10.32% | 44.62B | B- | ||
| +8.14% | 42.5B | B+ | ||
| +15.76% | 29.99B | B | ||
| +15.53% | 25.22B | A- | ||
| -5.88% | 24.14B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EMBC Stock
- Ratings Embecta Corp.
